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2-[18F]-fluoro-2-deoxy-D-glucose positron 
emission tomography/ computed tomography (FDG 
PET/CT) is routinely used in clinical oncology for the 
diagnosis of many different types of cancers, taking 
advantage of the high glucose avidity of neoplastic 
cells [1]. It is indeed notable that, cancer cells display 
an “addiction” to “aerobic” glycolysis, the so-called 
“Warburg effect”. However, plasticity in the 
metabolic reprogramming of cancer cells is far more 
complex, as genetic and phenotypic changes lead to 
metabolic heterogeneity of tumor cell populations. 
Factors in the microenvironment, such as the level of 
nutrients, oxygen, pH, and the presence of host 
stromal cells may influence cancer cell metabolism. As 
a consequence, a low FDG uptake by cancer cells may 
be related to a low glycolytic rate or to the use of 
alternative substrates. However, in certain tumors, the 
diagnostic accuracy of FDG-PET may be affected 
either by the size of lesion (if below the spatial 
resolution of PET/CT), or by the physiological 
urinary excretion rate of the tracer, or by the relatively 
high metabolic activity of surrounding tissue. Indeed, 
in the case of bladder, prostate, kidney, breast and 
endocrine gland cancers, FDG/PET analysis is not 
recommended for diagnosis [2].  
In order to improve the accuracy of FDG 
PET/CT imaging analysis, it is essential to seek 
further clarification in particular about the way in 
which cancer cells adapt to different metabolic 
profiles. In recent years, many authors have examined 
cancer metabolism and its reprogramming when cells 
are exposed to the influence of critical features of the 
tumor microenvironment, such as hypoxia and 
acidosis. Proliferating cancer cells use Warburg’s 
aerobic glycolysis to move to “anaerobic” glycolysis 
when challenged by hypoxia. Both of these metabolic 
conditions lead to glucose exhaustion and low 
extracellular pH (pHe), due to lactic acid secretion 
associated with a reduction in the draining activity of 
the lymphatic system. Acidosis in the tumor 
microenvironment, in turn, reprograms cancer cell 
metabolism towards a more oxidative phenotype. 
Thus, the microenvironment may lead to different 
FDG avidity of cancer cells. 
It has been reported quite recently that lactic 
acidosis inhibits breast cancer cell FDG uptake (e.g. in 
the human MDA-MB-231 triple-negative breast 
cancer cell line) [3]. Single cell suspensions were 
obtained from core and peripheral regions of 
subcutaneous tumors removed from mice. Next, FDG 
uptake was determined in cells of the two regions by 
radioluminescence (RLM) imaging. FDG uptake was 
significantly higher in cells isolated from the 
periphery of the tumors than in those from the core. 
Accordingly, there was evidence of mitochondrial 
redox differences between the core and the periphery 
of tumors in human breast cancer mouse xenografts 
[4]. Therefore, the microenvironment conditions 
which are considered capable of driving a change of 
FDG uptake are proliferation, hypoxia and acidosis. 
To corroborate RLM results further, the authors used 
gamma radiation counting, observing that the 
reduction of FDG uptake by cells from the core was 
promoted by either extracellular acidosis (both lactic 
and hydrochloric acidosis) or by sodium lactate, 
(although only at a high dosage). Several in vitro 
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reports have shown that a transient (24 hour) [5] or a 
chronic (8-10 week) [6] exposure to an acidic medium 
(pH 6.7-6.8) causes a shift of cancer cell metabolism 
from glycolytic to respiratory. Accordingly, this shift 
is associated with a decrease of glucose transporters, 
thus accounting for the reduction of FDG uptake.  
A further question is the case of oncogene-driven 
tumors. The constitutive activation of 
oncogene-dependent pathways might reinforce 
glycolytic metabolism and downregulate respiratory 
metabolism in cancer cells, via the reduction of both 
pyruvate kinase M2 (PKM2)-dependent conversion of 
phosphoenolpyruvate to pyruvate, and pyruvate flux 
to mitochondria [7]. This might explain the reverse 
association, observed in vivo, between FDG uptake 
and extracellular pH (pHe) in human epidermal 
growth factor receptor-2–positive (HER2+) breast 
cancer grafts. In this case, HER2 regulates key 
effectors of cellular metabolism such as the 
serine/threonine kinase Akt, increasing glucose 
metabolism and explaining the acidic pHe. As a 
consequence, only the inhibition of oncogene 
expression could lead to a significant shift from 
glycolysis to oxidative phosphorylation. 
Additional in vivo studies, dealing with the FGD 
uptake and pHe of cancer, have been carried out with 
conflicting results. In one study, the pHe of tumors, 
determined by chemical exchange saturation transfer 
(MRI-CEST) images, was found to be acidic (pH 6.7), 
and then FDG uptake was estimated by PET analysis. 
In order to validate CEST-pH mapping of tumors, 
animals were forced to drink bicarbonate-rich water 
to raise the pHe of tumors to almost neutral value (pH 
7.0-7.1), demonstrating a significant increase of 
positive pixels in tumors from sodium 
bicarbonate-treated animals when compared to those 
from untreated animals. Upon this validation of the 
combination of PET/MRI-CEST images, the authors 
realized that tumors with higher FDG uptake were 
associated with a lower pHe, while tumors with lower 
FDG uptake displayed a less acidic microenvironment 
[8]. 
Although we could not exclude the possibility 
that some metabolic differences were related to the 
different tumors analyzed, it is very difficult to infer a 
clear conclusion from these data. After FGD 
phosphorylation, brought about by hexokinase or 
glucokinase, FDG-6P is not available for metabolic 
activity. This “metabolic trap” is fundamental for 
FDG/PET analysis. However, a low amount of 
intracellular FDG might be removed slowly from the 
cell by the action of 6-phosphatase on FDG-6P. An 
additional element of complexity is the possible 
decrease or absence of glucose-6-phosphatase 
(G6Pase) activity in tumor cells, which might play a 
role in the modulation of glucose fermentation, e.g. 
some tumor regions of a renal cancer with reduced 
G6Pase exhibit a high FDG uptake [9]. The complex 
heterogeneity of cancer makes it difficult to predict a 
defined metabolic scenario.   
Figure 1 describes the active pathways of various 
cancer cell subpopulations, considering changes of 
major nutrients and the distance from blood supply, 
which are the prominent drivers of metabolic 
adaptation. Because of this, cancer cells located in 
proximity of a blood vessel are usually proliferative, 
when both PI3K/Akt signaling and c-Myc promote 
glucose uptake and glycolysis, and the already 
mentioned “Warburg effect” is present. This 
metabolic profile produces enough ATP at a fast rate 
but also generates important intermediates necessary 
for cell division. Further, glycolysis yields pyruvate, 
which, together with glutamine, sustains the TCA 
cycle for additional lipid and amino acid biosynthesis. 
However, most of pyruvate (80%) is converted to 
lactate and then excreted by specific transporters; this 
is necessary to maintain glycolytic flux. Although 
vasculature might remove the majority of protons 
and/or lactate, limiting the pH reduction, the 
extracellular medium becomes acidic.  
Moreover, in some tumor regions, despite the 
reduction in oxygen use, cancer cells move to 
HIF-1α-dependent anaerobic glycolysis when oxygen 
diffusion is limited and its percentage becomes less 
than 2%. In addition to this, the anaemia of 
cancer-bearing patients, occurring either as a 
paraneoplastic syndrome or as a common side effect 
of chemotherapy, contributes to the development of 
tissue hypoxia and to the activation of 
HIF-1α-dependent transcription factors. Major 
consequences of the switch to anaerobic glycolysis are 
a high and exclusive glucose uptake and the 
production of lactic acid, due to the HIF-1α promoting 
effect on glucose transporters and lactate 
dehydrogenase-A activity. The reduction of the 
proliferation level favors the resistance to apoptotic 
signals. Thus, both cancer cell sub-populations may 
acquire FDG but the anaerobic cells more so than the 
aerobic glycolytic cells. It should be noted that the 
tumor microenvironment contains host stromal cells, 
the so-called cancer-associated fibroblasts (CAF) 
which were observed to perform aerobic glycolysis 
(the so-called “reverse Warburg effect”), acquiring 
glucose and releasing lactate in normoxia [10]. 
Therefore, hypoxic CAF, carrying out an anaerobic 
glycolysis, concur to consume glucose and discard 
lactate in the extracellular environment. Interestingly, 
CAF contribute to extend the heterogeneity of cancer 
cells promoting the FDG uptake in tumor cells, as 
observed by micro-PET analysis [11]. Moreover, CAF 
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influence FDG uptake in a model of non-small cell 
lung cancer. When the tumor-bearing animals were 
fed, FDG accumulated in noncancerous stroma of the 
tumors, whereas, when mice were made to fast, the 
predominant FDG uptake was ascribed to hypoxic 
cancer cells [12].  
Furthermore, it has been demonstrated that the 
acidic microenvironment affects HIF-1α, which is the 
key glycolytic driver of hypoxic cancer cells. Indeed, 
when cancer cells are exposed, under hypoxic 
conditions (1% oxygen), to a slightly basic 
microenvironment (7.7 pHe), they express a very high 
level of HIF-1α as expected.  The level of HIF-1α 
expression is not reduced when cells are exposed to 
7.3 pHe, whereas it is severely reduced when cells are 
exposed to 6.8 pHe. HIF-1α completely disappears in 
cancer cells exposed to 6.3 pHe, under hypoxic 
conditions [13]. In addition, during the early phase of 
tumor growth, when oxygen tension is still high 
enough (approx. 2.5% oxygen), pHe is already 6.6. 
When tumors are larger than 500 mm3, oxygen level is 
around 1% and the pHe is approximately 6.4, 
suggesting that low pHe not only influences hypoxic 
cancer cells but also the “Warburg-addicted” cancer 
cells of oxygenated regions [14]. These findings 
indicate that acidosis, more than hypoxia, may 
represent the crucial factor in regulating cell 
metabolism, acting like a control trigger capable of 
switching cancer cell metabolism from glucose to 
other substrates. 
Thus, a different degree of lactate accumulation 
may adjust the level of glucose uptake, as: (i) the low 
amount of lactate generated by low-glycolytic tumor 
cells does not modify the low level of FDG uptake; (ii) 
a medium amount of lactate, released by 
intermediate-glycolytic tumor cells, partially affects 
FDG uptake; (iii) a high amount of lactate, produced 
by high-glycolytic tumor/stromal cells, finally leads 
to a reduced glycolysis in adjacent tumor cell 
subpopulations, determining a significant reduction 
of FDG uptake. 
The low pHe removes the inhibitory activity of 
the HIF-1α-dependent pyruvate dehydrogenase 
kinase-1 on pyruvate dehydrogenase, allowing the 
restoration of an electron flux through the oxidative 
phosphorylation. Thus, acidic cells, in a 0.5% (at least) 
oxygen microenvironment, may become oxidative 
using alternative substrates, whose lactate acquires a 
notable significance [15, 16]. 
 
 
Figure 1. From proliferation to quiescence and aggressiveness: The figure describes the scenario of FDG uptake by the diverse metabolic cancer cell subpopulations inside a 
proliferative tumor. Changes in pHe and lactate due to local modification (e.g. high interstitial pressure, local ischemia) may drive a continuous metabolic reprogramming limiting 
FDG uptake. A, FDG uptake/ metabolism; B tumor microenvironment; C microenvironmental condition and nutrients. 
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In addition, acidic cancer cells reprogram their 
bioenergetic preferences toward glutamine and fatty 
acids, extending the range of their possible alternative 
sources [17]. It is possible that chronically-addicted 
acidic cancer cells of a tumor mass, despite their 
reprogramming towards a more oxidative 
phosphorylation, maintain, in addition to the 
consumption of other substrates, some residual 
glucose uptake to be used for anaplerosis, which is 
critical for cell proliferation. Thus, chronic acidic cells 
might turn out to be weakly FDG positive. 
Although the acidic cancer cells subpopulations 
express a more resistant and aggressive phenotype, 
often associated with an epithelial-to-mesenchymal 
transition, they are only weakly proliferative [18]. 
Thus, we have suggested that an acidic 
microenvironment can constitute a perfect niche for 
dormant tumor cells endowed with all the 
characteristics useful for resistance to programmed 
cell death. Moreover, the niche of acidic cancer cells 
may support the re-expansion of cancer cells in the 
neighboring host tissues, which may be in search of 
new area of growth [19]. It is possible that the new 
wave of tumor growth may start from the 
acidic/invasive front of the tumor, recapitulating a 
novel cell heterogeneity, indicating that an acidic 
microenvironment might be also a niche for the 
survival and renewal of cancer stem cells [20]. 
Beyond the points we have suggested here, there 
is still much to learn concerning tumor 
microenvironment. The rapid reprogramming of the 
metabolic profile of cancer cells is also involved in the 
emergence of a cancer stem cell-like phenotype [19, 
20] and/or the acquisition of drug resistance [21, 22]. 
A critical non-invasive evaluation of the different 
aspects of tumor microenvironment might predict 
cancer aggressiveness and patient prognosis [23, 24]. 
Thus, in order to enhance the reliability of the crucial 
diagnostic tool represented by the use of FDG in 
medical imaging, we are convinced that the 
development of novel alternative tracers capable of 
estimating additional parameters such as 
intratumoral acidity should be pursued [25]. 
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